{"generic":"Palivizumab","drugs":["Palivizumab","Synagis"],"mono":{"0":{"id":"924765-s-0","title":"Generic Names","mono":"Palivizumab"},"1":{"id":"924765-s-1","title":"Dosing and Indications","sub":{"1":{"id":"924765-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>not effective for the treatment of respiratory syncytial virus and is not approved for this indication<\/li><li>safety and effectiveness in children greater than 24 months of age at the start of dosing have not been established<\/li><li><b>Respiratory syncytial virus infection, High risk patients; Prophylaxis:<\/b> 15 mg\/kg IM monthly beginning prior to, and continuing during the RSV season (typically November through April in northern hemisphere)<\/li><\/ul>"},"2":{"id":"924765-s-1-6","title":"Dose Adjustments","mono":"<b>cardiopulmonary bypass:<\/b> for infants and children requiring cardiopulmonary bypass and receiving palivizumab, administer a postoperative dose as soon as possible following the procedure even if this is sooner than a month from the previous dose "},"3":{"id":"924765-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Respiratory syncytial virus infection, High risk patients; Prophylaxis<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Cystic fibrosis - Respiratory syncytial virus infection; Prophylaxis<br\/>"}}},"3":{"id":"924765-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924765-s-3-9","title":"Contraindications","mono":"severe hypersensitivity reaction to palivizumab or other components of this product <br\/>"},{"id":"924765-s-3-10","title":"Precautions","mono":"<ul><li>anaphylaxis and anaphylactic shock, including fatal cases, and other severe acute hypersensitivity reactions have been reported on initial exposure or re-exposure; permanently discontinue if a severe hypersensitivity reaction occurs<\/li><li>immunological-based respiratory syncytial virus (RSV) diagnostic tests; interference leading to false-negative RSV test results may occur<\/li><li>thrombocytopenia or any coagulation disorder<\/li><li>report suspected adverse events to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"924765-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"924765-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"924765-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Rash (12%)<\/li><li><b>Other:<\/b>Fever (27%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Thrombocytopenia<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><\/ul>"},"6":{"id":"924765-s-6","title":"Drug Name Info","sub":{"0":{"id":"924765-s-6-17","title":"US Trade Names","mono":"Synagis<br\/>"},"2":{"id":"924765-s-6-19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"924765-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"924765-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"924765-s-7","title":"Mechanism Of Action","mono":"Palivizumab is a humanized monoclonal antibody directed against  the fusion protein of respiratory syncytial virus (RSV). Passive immunity is provided via blockage of the membrane fusion process. Cell-to-cell fusion of RSV-infected cells is also prevented.<br\/>"},"8":{"id":"924765-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"924765-s-8-23","title":"Absorption","mono":"Bioavailability, IM: 70% <br\/>"},"3":{"id":"924765-s-8-26","title":"Excretion","mono":"Total Body Clearance: 11 mL\/day <br\/>"},"4":{"id":"924765-s-8-27","title":"Elimination Half Life","mono":"20 to 24.5 days <br\/>"}}},"9":{"id":"924765-s-9","title":"Administration","mono":"<b>Intramuscular<\/b><br\/><ul><li>single dose vial does not require reconstitution or dilution<\/li><li>do not shake or vigorously agitate the vials<\/li><li>administer dose immediately after withdrawing from vial; do not re-enter vial<\/li><li>administer injection in anterolateral aspect of thigh; do not use gluteal muscle due to risk of sciatic nerve damage<\/li><li>injection volumes over 1 mL should be given in divided doses<\/li><\/ul>"},"10":{"id":"924765-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement<\/li><li>fever<\/li><li>respiratory function<\/li><li>signs\/symptoms of hypersensitivity reactions<\/li><\/ul>"},"11":{"id":"924765-s-11","title":"How Supplied","mono":"<b>Synagis<\/b><br\/>Intramuscular Solution: 50 MG\/0.5 ML, 100 MG\/ML<br\/>"},"13":{"id":"924765-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause rhinitis, upper respiratory infection, and wheezing.<\/li><li>This drug may cause gastrointestinal reactions such as vomiting, gastroenteritis, and diarrhea.<\/li><li>This drug may cause fever, otitis media, and rash.<\/li><li>Advise patient to seek treatment immediately for signs and symptoms of severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, such as hypotension, hypotonia, angioedema, pruritus, urticaria, respiratory failure, cyanosis, and dyspnea.<\/li><li>Advise patient to call healthcare professional if a treatment is missed, as drug should be given once per month during respiratory syncytial virus (RSV) season.<\/li><\/ul>"}}}